Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Neostigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 14/20 | 1.00 |
| ▸ | BCHE | P06276 | 6/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neostigmine SCHEMBL41128 | 1.00 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL8026154 | 0.98 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL29603805 | 0.98 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL34419 | 0.98 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL20425365 | 0.97 | ACHE (0.97) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL16228482 | 0.97 | ACHE (0.97) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL30029632 | 0.97 | ACHE (0.97) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL7576189 | 0.95 | ACHE (0.94) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL21772308 | 0.94 | ACHE (0.89) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL2028206 | 0.94 | ACHE (0.89) | ACHEBCHELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528819-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4665351-A1 | IMPROVING GLYMPHATIC-LYMPHATIC EFFLUX | University of Rochester (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| CN-119894225-A | Perovskite active layer film based on neostigmine bromide passivator, and preparation method and application thereof | 常州大学 | 2025-04-25 | — | — | CN | disclosed |
| EP-3207046-B1 | ACYCLIC CUCURBIT(N)URIL TYPE MOLECULAR CONTAINERS TO TREAT INTOXICATION AND DECREASE RELAPSE RATE IN SUBSTANCE ABUSE DISORDERS | UNIV MARYLAND (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024173675-A1 | IMPROVING GLYMPHATIC-LYMPHATIC EFFLUX | UNIVERSITY OF ROCHESTER (US) | 2024-08-22 | — | — | WO | disclosed |
| US-12023315-B2 | Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis | SOMERSET THERAPEUTICS, LLC (US) | 2024-07-02 | — | — | US | disclosed |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-117752806-A | Muscle relaxant antagonist composition and preparation method thereof | 西安丽彩医药研发有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230107032-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-06 | — | — | US | disclosed |
| US-20230098667-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11505555-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220331284-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS UTILIZING NEOSTIGMINE AND AN NK-1 ANTAGONIST FOR TREATING MYASTHENIA GRAVIS | DAS-MG, INC. | 2022-10-20 | — | — | US | disclosed |
| CN-115175911-A | Benzodiazepine derivatives, compositions and methods for the treatment of cognitive impairment | 艾吉因生物股份有限公司 | 2022-10-11 | — | — | CN | disclosed |
| US-20220274996-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2022-09-01 | — | — | US | disclosed |
| US-11414425-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220227724-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM | OAK RIDGE NATIONAL LABORATORY | 2022-07-21 | — | — | US | disclosed |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227724-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM | BCHE, ACHE, FHIT | ACHE 2/4885BCHE 1/4885LMNA 2990/4885 |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | ACHE 1356/4885BCHE 1124/4885LMNA 2061/4885 |
| US-11505555-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | ACHE 1366/4885BCHE 1082/4885LMNA 2504/4885 |
| US-12528819-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRE | ACHE 1281/4885BCHE 1127/4885LMNA 2079/4885 |
| US-11312721-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | ACHE 1300/4885BCHE 1059/4885LMNA 2260/4885 |
| US-20230107032-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | ACHE 1508/4885BCHE 1664/4885LMNA 2588/4885 |
| US-11414425-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRA1 | ACHE 1508/4885BCHE 1664/4885LMNA 2588/4885 |
| US-20220274996-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | ACHE 1356/4885BCHE 1124/4885LMNA 2061/4885 |
| US-20230098667-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | ACHE 1295/4885BCHE 1499/4885LMNA 2575/4885 |
| US-12291535-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GABRA5, GRM5, GABRA1 | ACHE 1508/4885BCHE 1664/4885LMNA 2588/4885 |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRB1 | ACHE 981/4885BCHE 341/4885LMNA 1853/4885 |
| US-20230134844-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | ACHE 1366/4885BCHE 1082/4885LMNA 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.